IS8358A - Disruptive RNA double-stranded with smooth ends and 3 'variants - Google Patents

Disruptive RNA double-stranded with smooth ends and 3 'variants

Info

Publication number: IS8358A
Authority: IS; Iceland
Prior art keywords: disruptive; stranded; variants; rna double; smooth ends
Prior art date: 2003-08-28

Application number

IS8358A

Other languages

Icelandic (is)

Inventor

Weiler Jan

Hall Jonathan

Bologna Jean-Charles

Jean-Charles Natt François

Häner Robert

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2006-03-17

Publication date

2006-03-17

2006-03-17 Application filed by Novartis Ag filed Critical Novartis Ag

2006-03-17 Publication of IS8358A publication Critical patent/IS8358A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

IS8358A 2003-08-28 2006-03-17 Disruptive RNA double-stranded with smooth ends and 3 'variants IS8358A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49851403P	2003-08-28	2003-08-28
PCT/EP2004/009599 WO2005021749A1 (en)	2003-08-28	2004-08-27	Interfering rna duplex having blunt-ends and 3’-modifications

Publications (1)

Publication Number	Publication Date
IS8358A true IS8358A (en)	2006-03-17

Family

ID=34272687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8358A IS8358A (en)	2003-08-28	2006-03-17	Disruptive RNA double-stranded with smooth ends and 3 'variants

Country Status (21)

Country	Link
US (2)	US20070203084A1 (en)
EP (3)	EP2338995A3 (en)
JP (2)	JP2007503803A (en)
KR (3)	KR20060087531A (en)
CN (2)	CN1845993B (en)
AU (1)	AU2004269150C1 (en)
BR (1)	BRPI0413146A (en)
CA (1)	CA2536333C (en)
CO (1)	CO5680494A2 (en)
EC (1)	ECSP066388A (en)
IL (1)	IL173565A (en)
IS (1)	IS8358A (en)
MA (1)	MA28029A1 (en)
MX (1)	MXPA06002216A (en)
NO (1)	NO20061345L (en)
NZ (1)	NZ545360A (en)
RU (2)	RU2399671C2 (en)
SG (1)	SG152279A1 (en)
TN (1)	TNSN06065A1 (en)
WO (1)	WO2005021749A1 (en)
ZA (1)	ZA200601003B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20060087531A (en)	2003-08-28	2006-08-02	노파르티스 아게	Interfering rna duplex having blunt-ends and 3'-modifications
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
US9074205B2 (en) *	2006-10-18	2015-07-07	Marina Biotech, Inc.	Nicked or gapped nucleic acid molecules and uses thereof
JP4900943B2 (en) *	2006-12-25	2012-03-21	独立行政法人産業技術総合研究所	Modified double-stranded RNA with excellent nuclease resistance and RNA interference effect
ES2428009T3 (en)	2007-07-05	2013-11-05	Novartis Ag	RRNAs to treat viral infections
EP2260102A1 (en)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
ES2562499T3 (en)	2009-12-09	2016-03-04	Nitto Denko Corporation	HSP47 expression modulation
EP3406720A1 (en)	2009-12-18	2018-11-28	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat hsf1-related diseases
US20110200582A1 (en)	2009-12-23	2011-08-18	Novartis Ag	Lipids, lipid compositions, and methods of using them
CN102770767A (en)	2010-02-10	2012-11-07	诺瓦提斯公司	Methods and compounds for muscle growth
US20130004519A1 (en)	2010-03-05	2013-01-03	Ruth Chiquet-Ehrismann	Smoci, tenascin-c and brain cancers
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
WO2011133876A2 (en) *	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
AU2011244335B2 (en)	2010-04-23	2015-06-04	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat Beta-ENaC-related diseases
US20130089538A1 (en)	2010-06-10	2013-04-11	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh	Treating cancer by modulating mammalian sterile 20-like kinase 3
US9181553B2 (en)	2011-06-06	2015-11-10	Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Method of treatment of breast cancers over-expressing the SHP2 signature genes
PT2734624T (en) *	2011-07-18	2018-05-24	Devgen Nv	Down regulating gene expression in insect pests
EA201490553A1 (en)	2011-09-02	2014-08-29	Новартис Аг	ORGANIC COMPOSITIONS FOR THE TREATMENT OF HSF1-CONNECTED DISEASES
US20140294732A1 (en)	2011-11-08	2014-10-02	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en)	2011-11-08	2013-05-16	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
KR20140091695A (en)	2011-11-15	2014-07-22	노파르티스 아게	Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
EP2800583A1 (en)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 and breast cancer
EP2802658A2 (en)	2012-01-09	2014-11-19	Novartis AG	Rnai agents to treat beta-catenin related diseases
WO2013144240A1 (en)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
EP3272868A1 (en)	2012-05-02	2018-01-24	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat kras-related diseases
US10125362B2 (en) *	2012-05-22	2018-11-13	Olix Pharmaceuticals, Inc.	RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en)	2012-07-05	2015-07-02	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	New treatment for neurodegenerative diseases
US20150224190A1 (en)	2012-07-06	2015-08-13	Mohamed Bentires-Alj	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014134255A2 (en)	2013-02-28	2014-09-04	Novartis Ag	Organic compositions to treat epas1-related diseases
KR102144777B1 (en) *	2013-06-19	2020-08-18	제이더블유중외제약 주식회사	A process for the preparation of crystalline Meropenem trihydrate
US20160178610A1 (en)	2013-08-07	2016-06-23	Friedrich Miescher Institute For Biomedical Research	New screening method for the treatment Friedreich's ataxia
US10519446B2 (en)	2013-10-04	2019-12-31	Novartis Ag	Organic compounds to treat hepatitis B virus
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
WO2015051044A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
US10227588B2 (en)	2013-10-04	2019-03-12	Novartis Ag	3′end caps for RNAi agents for use in RNA interference
WO2015051135A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Organic compositions to treat hepcidin-related diseases
KR101696704B1 (en) *	2013-12-17	2017-01-16	주식회사 인코드젠	Modified rna interference inducing nucleotides for blocking off-target effects and the use thereof
US20170137824A1 (en)	2014-06-13	2017-05-18	Indranil BANERJEE	New treatment against influenza virus
WO2016001830A1 (en)	2014-07-01	2016-01-07	Friedrich Miescher Institute For Biomedical Research	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP4223285A3 (en)	2014-07-16	2023-11-22	Novartis AG	Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3169784B1 (en)	2014-07-16	2020-06-10	Arrowhead Pharmaceuticals, Inc.	Rnai compositions to treat apoc3-related diseases
WO2016038550A1 (en)	2014-09-11	2016-03-17	Novartis Ag	Inhibition of prmt5 to treat mtap-deficiency-related diseases
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
WO2016089883A1 (en)	2014-12-01	2016-06-09	Novartis Ag	Compositions and methods for diagnosis and treatment of prostate cancer
WO2016193945A2 (en)	2015-06-05	2016-12-08	Novartis Ag	Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
WO2017072669A1 (en)	2015-10-28	2017-05-04	Friedrich Miescher Institute For Biomedical Research	Tenascin-w and biliary tract cancers
JOP20200228A1 (en)	2015-12-21	2017-06-16	Novartis Ag	Compositions and methods for decreasing tau expression
US9721645B1 (en)	2016-01-29	2017-08-01	Taiwan Semiconductor Manufacturing Company, Ltd.	SRAM arrays and methods of manufacturing same
WO2018047148A1 (en)	2016-09-12	2018-03-15	Novartis Ag	Compounds for the inhibition of mirna
WO2018083606A1 (en)	2016-11-01	2018-05-11	Novartis Ag	Methods and compositions for enhancing gene editing
EP3655004A2 (en)	2017-07-21	2020-05-27	Novartis AG	Compositions and methods to treat cancer
CR20200108A (en)	2017-09-11	2020-06-28	Arrowhead Pharmaceuticals Inc	AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEINA C-III (APOC3)
EP3788138A1 (en)	2018-05-02	2021-03-10	Novartis AG	Regulators of human pluripotent stem cells and uses thereof
WO2024134502A1 (en)	2022-12-20	2024-06-27	Novartis Ag	Engineered double-strand rna ligases and uses thereof
WO2024134505A1 (en)	2022-12-20	2024-06-27	Novartis Ag	Nucleic acid ligation method

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69033495T2 (en) *	1989-10-24	2000-07-20	Isis Pharmaceuticals, Inc.	2'-MODIFIED NUCLEOTIDES
US6005087A (en) *	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US6399754B1 (en) *	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US5670633A (en) *	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US6033909A (en) *	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
KR930016437A (en)	1992-01-22	1993-08-26	귀틀라인, 슈미트	Oligonucleotide Analogues, Methods for Making and Uses thereof
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
ES2231819T3 (en) *	1995-06-07	2005-05-16	Inex Pharmaceuticals Corp	PARTICULES OF NUCLEIC LIPIDO-ACID PREPARED THROUGH A NIPLEIC HYDROPHOBIC NIPLEIC ACID COMPLEX INTERMEDIATE AND USE TO TRANSFER GENES.
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
DE69841002D1 (en) *	1997-05-14	2009-09-03	Univ British Columbia	Highly effective encapsulation of nucleic acids in lipid vesicles
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
US6211349B1 (en) *	1998-12-30	2001-04-03	Oligos Etc., Inc.	Protonated/acidified nucleic acids and methods of use
WO2000044914A1 (en) *	1999-01-28	2000-08-03	Medical College Of Georgia Research Institute, Inc.	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en)	1999-01-30	2000-08-17	Roland Kreutzer	Method and medicament for inhibiting the expression of a given gene
GB9927444D0 (en)	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
DE10160151A1 (en)	2001-01-09	2003-06-26	Ribopharma Ag	Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
US20070026394A1 (en) *	2000-02-11	2007-02-01	Lawrence Blatt	Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
WO2003070918A2 (en) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Rna interference by modified short interfering nucleic acid
US20050233329A1 (en) *	2002-02-20	2005-10-20	Sirna Therapeutics, Inc.	Inhibition of gene expression using duplex forming oligonucleotides
US8202979B2 (en) *	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP1309726B2 (en)	2000-03-30	2018-10-03	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
US20030190635A1 (en) *	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
NZ525888A (en) *	2000-12-01	2006-04-28	Max Planck Gesellschaft	RNA interference mediating small RNA molecules
US20020132257A1 (en) *	2001-01-31	2002-09-19	Tony Giordano	Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20030175950A1 (en) *	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040019001A1 (en) *	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
EP1627061B1 (en)	2001-05-18	2009-08-12	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20070032441A1 (en) *	2001-05-18	2007-02-08	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
CA2448320A1 (en) *	2001-05-29	2002-12-05	Sirna Therapeutics, Inc.	Ribozyme based treatment of female reproductive diseases
US20090247606A1 (en) *	2001-08-28	2009-10-01	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8258288B2 (en) *	2002-02-20	2012-09-04	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
BRPI0313202A8 (en) *	2002-08-05	2016-08-16	Atugen Ag	ADDITIONAL WAYS TO INTERFERE WITH RNA MOLECULES
DK1389637T3 (en) *	2002-08-05	2012-09-03	Silence Therapeutics Ag	Interfering RNA molecules with blunt ends
EP1608733B1 (en) *	2003-04-02	2011-12-07	Dharmacon, Inc.	Modified polynucleotides for use in rna interference
US20070270360A1 (en) *	2003-04-15	2007-11-22	Sirna Therapeutics, Inc.	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
EP1620544B1 (en) *	2003-04-17	2018-09-19	Alnylam Pharmaceuticals Inc.	MODIFIED iRNA AGENTS
WO2005009346A2 (en) *	2003-06-24	2005-02-03	Mirus Corporation	Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
KR20060087531A (en)	2003-08-28	2006-08-02	노파르티스 아게	Interfering rna duplex having blunt-ends and 3'-modifications
EP2399924B1 (en)	2004-05-27	2015-01-28	Alnylam Pharmaceuticals, Inc.	Nuclease resistant double-stranded ribonucleic acid
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds

2004
- 2004-08-27 KR KR1020067004048A patent/KR20060087531A/en not_active Application Discontinuation
- 2004-08-27 US US10/569,927 patent/US20070203084A1/en not_active Abandoned
- 2004-08-27 EP EP10184568A patent/EP2338995A3/en not_active Withdrawn
- 2004-08-27 EP EP12151831A patent/EP2489737A1/en not_active Withdrawn
- 2004-08-27 CA CA2536333A patent/CA2536333C/en not_active Expired - Lifetime
- 2004-08-27 KR KR1020087007645A patent/KR101059315B1/en not_active IP Right Cessation
- 2004-08-27 WO PCT/EP2004/009599 patent/WO2005021749A1/en active Application Filing
- 2004-08-27 RU RU2006109547/13A patent/RU2399671C2/en not_active IP Right Cessation
- 2004-08-27 EP EP04764573A patent/EP1660657A1/en not_active Ceased
- 2004-08-27 AU AU2004269150A patent/AU2004269150C1/en not_active Expired
- 2004-08-27 NZ NZ545360A patent/NZ545360A/en not_active IP Right Cessation
- 2004-08-27 SG SG200902906-7A patent/SG152279A1/en unknown
- 2004-08-27 KR KR1020117000474A patent/KR20110007263A/en not_active Application Discontinuation
- 2004-08-27 MX MXPA06002216A patent/MXPA06002216A/en active IP Right Grant
- 2004-08-27 JP JP2006524342A patent/JP2007503803A/en active Pending
- 2004-08-27 CN CN2004800249803A patent/CN1845993B/en not_active Expired - Lifetime
- 2004-08-27 CN CN2010101678324A patent/CN101914533B/en not_active Expired - Fee Related
- 2004-08-27 BR BRPI0413146-0A patent/BRPI0413146A/en not_active IP Right Cessation
2006
- 2006-02-03 ZA ZA200601003A patent/ZA200601003B/en unknown
- 2006-02-06 IL IL173565A patent/IL173565A/en active IP Right Grant
- 2006-02-22 EC EC2006006388A patent/ECSP066388A/en unknown
- 2006-02-27 TN TNP2006000065A patent/TNSN06065A1/en unknown
- 2006-03-08 MA MA28861A patent/MA28029A1/en unknown
- 2006-03-17 IS IS8358A patent/IS8358A/en unknown
- 2006-03-21 CO CO06027688A patent/CO5680494A2/en not_active Application Discontinuation
- 2006-03-24 NO NO20061345A patent/NO20061345L/en not_active Application Discontinuation
2008
- 2008-12-18 US US12/338,601 patent/US8097716B2/en active Active
2010
- 2010-05-14 RU RU2010119292/10A patent/RU2010119292A/en not_active Application Discontinuation
- 2010-08-26 JP JP2010189117A patent/JP2011160796A/en active Pending

Also Published As

Publication number	Publication date
CO5680494A2 (en)	2006-09-29
MA28029A1 (en)	2006-07-03
EP2489737A1 (en)	2012-08-22
TNSN06065A1 (en)	2007-10-03
US20070203084A1 (en)	2007-08-30
RU2010119292A (en)	2011-12-10
JP2011160796A (en)	2011-08-25
RU2006109547A (en)	2007-10-10
SG152279A1 (en)	2009-05-29
EP1660657A1 (en)	2006-05-31
NO20061345L (en)	2006-05-29
JP2007503803A (en)	2007-03-01
CN1845993B (en)	2010-06-23
CN1845993A (en)	2006-10-11
MXPA06002216A (en)	2006-04-27
KR20060087531A (en)	2006-08-02
EP2338995A2 (en)	2011-06-29
IL173565A (en)	2012-07-31
CN101914533B (en)	2013-06-19
KR20110007263A (en)	2011-01-21
CA2536333C (en)	2013-01-08
KR20080034046A (en)	2008-04-17
EP2338995A3 (en)	2012-01-11
KR101059315B1 (en)	2011-08-24
ECSP066388A (en)	2006-08-30
BRPI0413146A (en)	2006-10-03
NZ545360A (en)	2009-06-26
US20090192113A1 (en)	2009-07-30
US8097716B2 (en)	2012-01-17
CN101914533A (en)	2010-12-15
AU2004269150B2 (en)	2009-06-04
WO2005021749A1 (en)	2005-03-10
RU2399671C2 (en)	2010-09-20
AU2004269150A1 (en)	2005-03-10
CA2536333A1 (en)	2005-03-10
AU2004269150C1 (en)	2010-11-18
IL173565A0 (en)	2006-07-05
ZA200601003B (en)	2007-04-25

Publication	Publication Date	Title
IS8358A (en)	2006-03-17	Disruptive RNA double-stranded with smooth ends and 3 'variants
DK1711207T3 (en)	2013-03-11	Interferon-alpha antibodies and their use
DK1495053T3 (en)	2012-09-24	Angiopoietin-2 and angiopoietin-1-specific binders
DK3266791T3 (en)	2021-03-01	MARKED NUCLEOTIDES
IS8153A (en)	2005-11-28	Immunosuppressants and preparations
NO20053974D0 (en)	2005-08-25	Tienopyrimidine Compounds and Their Use.
DE60239828D1 (en)	2011-06-01	ÜR
NO20024355L (en)	2002-11-12	Nucleoside Compounds and Uses thereof
DK1417175T3 (en)	2013-10-28	SUBSTITUTED DIHYDRO-3-HALO-1H-PYRAZOL-5-CARBOXYLATES AND PREPARATION AND USE THEREOF
DE60236599D1 (en)	2010-07-15	ANTHROPODICIDES ANTHRANILAMIDES
ATE557095T1 (en)	2012-05-15	REPLICATIVE IN VIVO GENE TARGETING
DE50208638D1 (en)	2006-12-21	catheter
DK1337370T3 (en)	2006-04-10	Submersible inlet nozzle and use thereof
DK2301583T3 (en)	2012-12-10	Lentivirus vector-mediated gene transfer and applications thereof
DE602004000485D1 (en)	2006-05-11	afterburning
NO20042693L (en)	2004-08-25	Catheter preparation and applications thereof
NO20024617L (en)	2002-11-13	Aryl and heteroarylsulfonates
FIU20010462U0 (en)	2001-12-04	Cradle
DE50214325D1 (en)	2010-05-20	One strip-overhead goal
FR2827943B3 (en)	2003-08-29	PROFILE IN C
DE60219418D1 (en)	2007-05-24	SILANOLLPHENOL AND NAPHTHOLE
NO20053898D0 (en)	2005-08-19	Use and proceeding at footballshoes
NO20014350D0 (en)	2001-09-07	Puzzle
ITMI20011210A0 (en)	2001-06-08	CORTICOSTEROIDS-21-GLYCOLATES AND 21-ACYLGLYCOLATES
SE0100096D0 (en)	2001-01-12	Tissue specific genes and their promoters - apoptosis